Have a feature idea you'd love to see implemented?
Let us know!
ORMP Oramed Pharmaceuticals Inc
Price (delayed)
$2.355
Market cap
$96.01M
P/E Ratio
4.62
Dividend/share
N/A
EPS
$0.51
Enterprise value
$11.74M
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and
Highlights
The EPS has surged by 200% year-on-year and by 96% since the previous quarter
The net income has soared by 100% QoQ
The gross profit has plunged by 100% from the previous quarter and by 100% YoY
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Key stats
What are the main financial stats of ORMP
Market
Valuations
Earnings
Shares outstanding
40.77M
Market cap
$96.01M
Enterprise value
$11.74M
Price to earnings (P/E)
4.62
Price to book (P/B)
0.54
Price to sales (P/S)
N/A
EV/EBIT
1.16
EV/EBITDA
1.13
EV/Sales
N/A
Revenue
$0
EBIT
$10.14M
EBITDA
$10.36M
Free cash flow
-$1.55M
Per share
Balance sheet
Liquidity
EPS
$0.51
Free cash flow per share
-$0.04
Book value per share
$4.36
Revenue per share
$0
TBVPS
$4.5
Total assets
$184.22M
Total liabilities
$8.07M
Debt
$486,000
Equity
$177.07M
Working capital
$149.54M
Debt to equity
0
Current ratio
41.06
Quick ratio
40.92
Net debt/EBITDA
-8.14
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
9.9%
Return on equity
12.7%
Return on invested capital
5.7%
Return on capital employed
5.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORMP stock price
How has the Oramed Pharmaceuticals stock price performed over time
Intraday
-1.05%
1 week
1.07%
1 month
-5.42%
1 year
8.03%
YTD
1.95%
QTD
-3.48%
Financial performance
How have Oramed Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.87M
Net income
$20.86M
Gross margin
N/A
Net margin
N/A
The gross profit has plunged by 100% from the previous quarter and by 100% YoY
The net income has soared by 100% QoQ
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The operating income has surged by 52% year-on-year and by 4.9% since the previous quarter
Growth
What is Oramed Pharmaceuticals's growth rate over time
Valuation
What is Oramed Pharmaceuticals stock price valuation
P/E
4.62
P/B
0.54
P/S
N/A
EV/EBIT
1.16
EV/EBITDA
1.13
EV/Sales
N/A
The EPS has surged by 200% year-on-year and by 96% since the previous quarter
The P/B is 75% less than the 5-year quarterly average of 2.2 and 8% less than the last 4 quarters average of 0.6
The equity has grown by 17% YoY and by 6% from the previous quarter
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
Efficiency
How efficient is Oramed Pharmaceuticals business performance
The ROE has soared by 195% YoY and by 92% from the previous quarter
The ROA has soared by 179% year-on-year and by 90% since the previous quarter
The company's return on invested capital has surged by 132% YoY and by 14% QoQ
Dividends
What is ORMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORMP.
Financial health
How did Oramed Pharmaceuticals financials performed over time
Oramed Pharmaceuticals's total liabilities has shrunk by 79% QoQ but it has increased by 43% YoY
Oramed Pharmaceuticals's quick ratio has shrunk by 71% YoY
ORMP's debt is 100% lower than its equity
Oramed Pharmaceuticals's debt to equity has shrunk by 100% QoQ
ORMP's debt has shrunk by 99% QoQ and by 33% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.